The store will not work correctly when cookies are disabled.
5-(Benzo[d][1,3]dioxol-5-yl)-2-methyl-3-(pyridin-2-yl)pyrazolo[1,5-a]pyrimidin-7(4H)-one
ID: ALA3718833
PubChem CID: 70925679
Max Phase: Preclinical
Molecular Formula: C19H14N4O3
Molecular Weight: 346.35
Molecule Type: Small molecule
This compound is available for customization.
Associated Items:
Names and Identifiers
Canonical SMILES: Cc1nn2c(=O)cc(-c3ccc4c(c3)OCO4)[nH]c2c1-c1ccccn1
Standard InChI: InChI=1S/C19H14N4O3/c1-11-18(13-4-2-3-7-20-13)19-21-14(9-17(24)23(19)22-11)12-5-6-15-16(8-12)26-10-25-15/h2-9,21H,10H2,1H3
Standard InChI Key: VZTUFVJCFFAAOI-UHFFFAOYSA-N
Molfile:
RDKit 2D
26 30 0 0 0 0 0 0 0 0999 V2000
-1.0028 1.5132 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-2.3155 0.7475 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-2.3155 -0.7475 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.0028 -1.5132 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
0.2917 0.7475 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
0.2917 -0.7475 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.7138 -1.2033 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.5889 0.0182 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.7138 1.2033 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-0.9991 2.7132 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
-3.6168 -1.4950 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.1852 -2.6281 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.6221 -3.0405 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
3.9838 -4.4963 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.9039 -5.5373 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.4624 -5.1227 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.1007 -3.6669 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-3.6222 -3.0136 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-6.2317 -1.4807 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-4.9066 -0.7366 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-6.2271 -2.9846 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-4.9381 -3.7419 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-5.2653 -5.1989 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
-6.7304 -5.3532 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-7.3404 -3.9800 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
3.7889 0.0269 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
6 4 1 0
5 1 1 0
1 2 1 0
2 3 2 0
3 4 1 0
5 6 1 0
6 7 2 0
7 8 1 0
8 9 2 0
9 5 1 0
1 10 2 0
3 11 1 0
12 13 2 0
13 14 1 0
14 15 2 0
15 16 1 0
16 17 2 0
17 12 1 0
7 12 1 0
11 18 2 0
18 22 1 0
21 19 1 0
19 20 2 0
20 11 1 0
21 22 2 0
22 23 1 0
23 24 1 0
24 25 1 0
25 21 1 0
8 26 1 0
M END
Associated Targets(Human)
Molecule Features
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
Drug Indications
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanisms of Action
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Calculated Properties
Molecular Weight: 346.35 | Molecular Weight (Monoisotopic): 346.1066 | AlogP: 2.79 | #Rotatable Bonds: 2 |
Polar Surface Area: 81.51 | Molecular Species: NEUTRAL | HBA: 6 | HBD: 1 |
#RO5 Violations: ┄ | HBA (Lipinski): 7 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): ┄ |
CX Acidic pKa: 10.97 | CX Basic pKa: 2.89 | CX LogP: 1.97 | CX LogD: 1.97 |
Aromatic Rings: 4 | Heavy Atoms: 26 | QED Weighted: 0.60 | Np Likeness Score: -1.02 |
References
1. (2012) Heterocyclic compounds for the inhibition of pask, |
2. (2012) Heterocyclic compounds for the inhibition of pask, |